Breast cancer and gender-affirming hormone therapy for transgender and gender-diverse (TGD) individuals

Elizabeth J. Cathcart-Rake,Kathryn J. Ruddy,Amye J. Tevaarwerk,Aminah Jatoi
DOI: https://doi.org/10.1016/j.maturitas.2024.107913
IF: 5.11
2024-01-19
Maturitas
Abstract:Transgender and gender-diverse (TGD) individuals are at risk for breast cancer, but are less likely to undergo screening mammograms and appear to suffer poorer cancer-related outcomes than cisgender women. Gender-affirming hormone therapy (GAHT) may be lifesaving for TGD individuals from the perspective of affirming their core identities; however, the effects of GAHT on cancer development, progression, and outcomes are poorly understood.
obstetrics & gynecology,geriatrics & gerontology,gerontology
What problem does this paper attempt to address?